Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + HAIC FOLFOX + apatinib for first-line unresectable advanced hepatocellular carcinoma
ChiCTR2100045971Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Nanyang Medical College
- Start
- May 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, Rivoceranib, fluorouracil, folinic acid and oxaliplatin in hepatocellular carcinoma (HCC), sponsored by The First Affiliated Hospital of Nanyang Medical College. Primary endpoints: Progression-free survival and Objective response rate. Started May 2021; status: recruiting.
02
Drugs
camrelizumabRivoceranibfluorouracilfolinic acidoxaliplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100045971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045971.